Aura Biosciences
AURA
35 hedge funds and large institutions have $300M invested in Aura Biosciences in 2022 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
36% more capital invested
Capital invested by funds: $220M → $300M (+$79.7M)
9% more funds holding
Funds holding: 32 → 35 (+3)
2.28% more ownership
Funds ownership: 44.78% → 47.06% (+2.3%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.86M |
| 2 |
Barclays
London,
United Kingdom
|
+$1.14M |
| 3 |
UOC
UBS O'Connor
Chicago,
Illinois
|
+$933K |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
+$791K |
| 5 |
State Street
Boston,
Massachusetts
|
+$720K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
CAAS Capital Management
New York
|
-$170K |
| 2 |
JP Morgan Chase
New York
|
-$75.6K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$66K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$39K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$36.1K |
AURA Hedge Fund Activity: Q1 2022 in Review
35 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Aura Biosciences (AURA) for Q1 2022, worth a combined $300M — up 36% from $220M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AURA positions and 3 closed out — a net gain of 3 holders — while 14 added to existing stakes and 8 trimmed.
The largest buyer was Nantahala Capital Management, adding an estimated $3.86M. The largest seller was CAAS Capital Management, exiting entirely with an estimated $170K sold.
- 35 institutional investors held Aura Biosciences (AURA) as of Q1 2022, up from 32 in Q4 2021.
- Funds reported $300M of Aura Biosciences stock for Q1 2022, up 36% quarter-over-quarter.
- 6 funds opened new Aura Biosciences positions in Q1 2022 and 3 closed out, a net change of +3 holders.
- The largest Aura Biosciences buyer in Q1 2022 was Nantahala Capital Management, an estimated $3.86M added.
- The largest Aura Biosciences seller in Q1 2022 was CAAS Capital Management, an estimated $170K sold.
Based on aggregated 13F filings for Q1 2022.